StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by Str8Shooter88on Nov 02, 2016 3:07pm

54 Views

Post# 25417263

RE:RE:RE:RE:RE:RE:RE:RE:RE:So far its a medical discussion

Put lil pbay on ignore. He don't know shiit. Lying sack of poo is all.

brad129 wrote: Even with 3000 tests a month to start with it sure beats exas and as for the pbay startup (you know business cycle) we aren't supposed to be here yet it takes months to staff up and get facilities running. So if we are anywhere close to 3000 tests per month already I am extremely happy with that.

LithLover wrote:
I believe it was mentioned before that 3,000 test per month ($750,000/month or $9 million a year)) was the break even for profitability.